An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Backgroundβ-glucan has been reported to be a potential natural immune modulator for tumor growth inhibition. We aimed to evaluate the efficacy and safety of β-glucan plus immunotherapy and chemotherapy in the first-line treatment of advanced gastric adenocarcinoma.MethodsThis is a phase IB, prospect...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, Dongsheng Chen, Hanjue Dai, Qingying Xian, Wenyu Zhu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	β-glucan camrelizumab chemotherapy first-line gastric cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1448485/full